Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications
Citations Over TimeTop 15% of 2004 papers
Abstract
No preclinical method to evaluate potential new medications for essential tremor (ET) is available currently. Although harmaline tremor is a well known animal model of ET, it has not found utility as a preclinical drug screen and has not been validated with anti-ET medications. We measured harmaline tremor in rats (10 mg/kg s.c.) and mice (20 mg/kg s.c.) with a load sensor under the cage floor and performed spectral analysis on 20-minute epochs. The motion power over the tremor frequency bandwidth (8-12 Hz in rats; 10-16 Hz in mice) was divided by the motion power over the full motion frequency range (0-15 Hz in rats; 0-34 Hz in mice). The use of these measures greatly reduced data variability, permitting experiments with small sample sizes. Three drugs that suppress ET (propranolol, ethanol, and octanol) all significantly suppressed harmaline-induced tremor. We propose that, with this methodology, harmaline-induced tremor may be useful as a preclinical method to identify potential medications for ET.
Related Papers
- → Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications(2004)116 cited
- → Harmaline Tremor: Underlying Mechanisms in a Potential Animal Model of Essential Tremor(2012)82 cited
- → Harmaline Tremor: Underlying Mechanisms in a Potential Animal Model of Essential Tremor(2012)76 cited
- → Development of Harmaline-induced Tremor in a Swine Model(2017)9 cited
- → Mapping BOLD Activation by Pharmacologically Evoked Tremor in Swine(2019)8 cited